Hepatic Arterial Infusion of Oxaliplatin plus Fluorouracil/Leucovorin versus Sorafenib for Advanced Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer worldwide [1] and advanced-stage is found in 25%-70% of HCC at diagnosis with a median overall survival (OS) of only 4.2-7.9 months due to limited treatment options. [2,3] To date, sorafenib is still the only treatment shown to extend OS for advanced HCC (Ad-HCC). [4] However, low response rates [2], modest survival advantages [3], high-level heterogeneity of individual response [5] and insensitivity for population with HBV infection [6], such limitations of sorafenib prohibit its widespread use in Ad-HCC and more alternative therapies are urgently required at present.

Source: Journal of Hepatology - February 19, 2018 Category: Gastroenterology Authors: Ning Lyu, Yanan Kong, Luwen Mu, Youen Lin, Jibin Li, Yaru Liu, Zhenfeng Zhang, Lie Zheng, Haijing Deng, Shaolong Li, Qiankun Xie, Rongping Guo, Ming Shi, Li Xu, Xiuyu Cai, Peihong Wu, Ming Zhao Source Type: research